功能性内镜鼻窦手术治疗慢性鼻窦炎的评估：一项使用鼻窦结局测试-22的前瞻性结局研究

文献信息

中文摘要

背景： 慢性鼻窦炎（CRS）是一种常见且使人衰弱的疾病，可导致生活质量显著受损。当药物治疗失败时，功能性内镜鼻窦手术（FESS）是公认的手术干预方式；然而，客观的结局测量仍然至关重要。本研究使用经过验证的鼻窦结局测试-22（SNOT-22）患者报告结局测量工具评估FESS的疗效。
材料与方法： 对33例接受FESS的CRS患者进行了一项前瞻性观察性研究。在术前以及术后1周、4周和3个月记录SNOT-22评分。使用配对t检验将每个随访时间点的平均评分与基线进行比较。
结果： 术前SNOT-22平均评分为42.03（±6.64）。术后1周（9.94 ± 2.26）、4周（5.61 ± 1.97）和3个月（4.58 ± 1.41）观察到显著降低，分别代表降低76.4%、86.7%和89.1%。所有比较均具有统计学显著性（P < 0.001）。
结论： FESS可使CRS患者的鼻窦症状和生活质量获得显著且持续的改善。SNOT-22是监测手术结局的可靠且敏感的工具。这些发现进一步支持FESS作为药物难治性CRS的金标准手术治疗。

英文摘要

BACKGROUND: Chronic rhinosinusitis (CRS) is a prevalent, debilitating condition causing significant impairment of quality of life. Functional Endoscopic Sinus Surgery (FESS) is the accepted surgical intervention when medical treatment fails; however, objective outcome measurement remains essential. This study evaluates the efficacy of FESS using the validated Sinonasal Outcome Test-22 (SNOT-22) patient-reported outcome measure.
MATERIALS AND METHODS: A prospective observational study was conducted on 33 patients with CRS who underwent FESS. SNOT-22 scores were recorded preoperatively and postoperatively at 1 week, 4 weeks, and 3 months. Paired t-tests were used to compare mean scores at each follow-up time point against baseline.
RESULTS: The mean preoperative SNOT-22 score was 42.03 (±6.64). Significant reductions were observed at 1 week (9.94 ± 2.26), 4 weeks (5.61 ± 1.97), and 3 months (4.58 ± 1.41) post-surgery, representing reductions of 76.4%, 86.7%, and 89.1%, respectively. All comparisons were statistically significant (P < 0.001).
CONCLUSIONS: FESS produces substantial and sustained improvement in sinonasal symptoms and quality of life in CRS patients. The SNOT-22 is a reliable and sensitive tool for monitoring surgical outcomes. These findings reinforce FESS as the gold standard surgical treatment for medically refractory CRS.